Key Findings From the Phase 3 STELLAR Study
Orbus Therapeutics, Inc. has announced the significant outcomes of its Phase 3 STELLAR clinical study, shedding light on treatment strategies for recurrent grade 3 astrocytoma—a rare and aggressive brain tumor. The study results highlight the potential of eflornithine combined with lomustine in improving patient outcomes, marking a crucial development in neuro-oncology.
About the Clinical Study
The Phase 3 STELLAR study involved a total of 343 patients diagnosed with grade 3 astrocytoma, a type of brain cancer known for its challenging prognosis. The participation of patients was based on their IDH mutation status, ensuring a thorough analysis of the treatment's effectiveness. Notably, the study presented evidence of improved overall survival (OS) and progression-free survival (PFS) among those treated with the combination therapy.
Comparative Analysis of Treatment Effects
Results indicate that patients receiving the combined treatment of eflornithine and lomustine experienced a median OS of 34.9 months, compared to 23.5 months for those receiving lomustine alone. This indicates a significant survival advantage, showcasing the potential benefits of this combination therapy in managing the disease.
Patient Outcomes and Study Design
Despite disappointing results in the broader intent-to-treat (ITT) population, the subset analysis provided compelling evidence for the efficacy of the treatment specifically among patients with recurrent IDH mutant grade 3 astrocytoma. As discussed by Jason Levin, the President and CEO of Orbus Therapeutics, the findings demonstrate a notable step forward in an area where treatment options have been limited.
Importance of WHO Tumor Classification
The results of the STELLAR study were given added context by referencing the World Health Organization's (WHO) tumor classification system. This system is vital for categorizing brain tumors based on biological and histological characteristics, allowing for tailored treatment approaches. The recent updates to this classification reflect advancements in understanding the genetic underpinnings of these tumors.
Understanding Eflornithine's Role
Eflornithine is a groundbreaking treatment option, recognized for its ability to inhibit key metabolic pathways in cancer cells. This drug has received Orphan Drug Designation and Breakthrough Therapy Designation from the FDA, highlighting its potential as a vital treatment for patients battling anaplastic glioma. The favorable safety profile and the absence of new safety signals are encouraging for its continued development.
About Orbus Therapeutics
Orbus Therapeutics stands at the forefront of biopharmaceutical innovation, focusing on therapies for rare diseases with limited treatment alternatives. Their dedication to improving patient care is evident in the rigorous research and clinical trials they undertake. As they continue to explore new frontiers in treatment, their commitment to patients remains unwavering.
For media inquiries, contact:
Jason Levin
Email: jason.levin@orbustherapeutics.com
Media:
Kelli Perkins
Email: kelli@redhousecomms.com
Frequently Asked Questions
What are the main findings of the Phase 3 STELLAR study?
The study reveals significant improvements in overall and progression-free survival for patients with recurrent grade 3 astrocytoma treated with eflornithine combined with lomustine.
How does eflornithine work?
Eflornithine targets and inhibits ornithine decarboxylase, a critical enzyme involved in cancer cell growth, making it a promising treatment option for brain tumors.
Who is Orbus Therapeutics?
Orbus Therapeutics is a late-stage biopharmaceutical company dedicated to developing therapies for rare diseases, specifically focusing on neuro-oncology.
What is the significance of the WHO tumor classification?
The WHO classification helps standardize cancer diagnoses globally, guiding treatment decisions based on tumor characteristics.
What can we expect from future research by Orbus Therapeutics?
Orbus is committed to further exploring effective treatments for rare diseases, leveraging innovative clinical research to enhance patient care.
